Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18y≤Age≤65y, male or female~* KPS≥70~* Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction with inoperable locally advanced or recurrent and/or metastatic disease~* At least one measurable lesion, according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1), assessed using imaging techniques (CT or MRI)~* No prior anti-tumor treatment or an interval of at least 6 months from the last adjuvant chemotherapy, and an interval of at least 4 weeks from the last radical radiation therapy~* No major organ disorder, with normal liver, kidney and heart function~* Laboratory test must meet the following criteria: hemoglobin (HGB) ≥90g/L, neutrophil count ≥1.5×109/L, platelet count ≥100×109/L, creatinine clearance rate (CCr) ≥60ml/min, total bilirubin (TBil) ≤1.5 upper normal limitation (UNL), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 UNL (For patients with liver metastasis, the AST/ALT must be ≤5.0 UNL), blood glucose ≤11.1 mmol/L~* Life expectancy of at least 12 weeks~* Signed informed consent~* For women with child bearing potential, a negative serum or urine pregnancy test result should be obtained before enrollment~Exclusion Criteria:~* Progression from prior palliative treatment with capecitabine- or docetaxel-based regimen~* Serious uncontrolled systemic illness or medical condition: congestive heart failure, unstable angina, history of documented myocardial infarction within 6 months, uncontrolled hypertension and high risk uncontrollable arrhythmias; Obvious neurological or mental abnormalities including mental disorder, epileptic dementia, which affect compliance; Uncontrolled acute infections; Uncontrolled peptic ulcer, diabetes or other contraindication for corticosteroid therapy~* Inability to take or absorb oral medicine~* Concurrent administration of any other investigational drug, or have been enrolled in other clinical trial with investigational drug treatment within the 30 days of start of study treatment~* Presence of neuropathy ≥grade 1 according to NCI-CTCAE V4.0~* Hypersensitivity or known or suspicious allergic to any of the study drugs~* Pregnant or lactated women~* Unsuitable for the study or other chemotherapy determined by investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- H-A: ERCC1 High Expression Group A (Type: ACTIVE_COMPARATOR): XP：Capecitabine+Cisplatin
- H-B: ERCC1 High Expression Group B (Type: EXPERIMENTAL): DX：Docetaxel+Capecitabine
- L: ERCC1 Low Expression Group (Type: ACTIVE_COMPARATOR): XP：Capecitabine+Cisplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues